IN2014MN02485A - - Google Patents
Info
- Publication number
- IN2014MN02485A IN2014MN02485A IN2485MUN2014A IN2014MN02485A IN 2014MN02485 A IN2014MN02485 A IN 2014MN02485A IN 2485MUN2014 A IN2485MUN2014 A IN 2485MUN2014A IN 2014MN02485 A IN2014MN02485 A IN 2014MN02485A
- Authority
- IN
- India
- Prior art keywords
- methyl
- pentahydroxyhexyl
- dihydroquinoline
- carboxamide
- oxo
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- OQZQXOFJGSSYNX-UHFFFAOYSA-N 1,2-dihydroquinoline-3-carboxamide Chemical compound C1=CC=C2NCC(C(=O)N)=CC2=C1 OQZQXOFJGSSYNX-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- -1 pentahydroxyhexyl Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 abstract 1
- 229960004577 laquinimod Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644054P | 2012-05-08 | 2012-05-08 | |
| PCT/US2013/039911 WO2013169746A2 (fr) | 2012-05-08 | 2013-05-07 | N-ethyl-4-hydroxyl-1-méthyl-5-(méthyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phényl-1,2-dihydroquinoléine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02485A true IN2014MN02485A (fr) | 2015-07-17 |
Family
ID=49551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2485MUN2014 IN2014MN02485A (fr) | 2012-05-08 | 2013-05-07 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8809537B2 (fr) |
| EP (1) | EP2697201A4 (fr) |
| KR (1) | KR20150022816A (fr) |
| CN (1) | CN104395291B (fr) |
| AR (1) | AR090975A1 (fr) |
| AU (1) | AU2013259779B2 (fr) |
| BR (1) | BR112014028121A2 (fr) |
| CA (1) | CA2873258A1 (fr) |
| EA (1) | EA201492029A1 (fr) |
| HK (1) | HK1207080A1 (fr) |
| IL (1) | IL235338A0 (fr) |
| IN (1) | IN2014MN02485A (fr) |
| MX (1) | MX2014013664A (fr) |
| NZ (1) | NZ630549A (fr) |
| SG (1) | SG11201407447XA (fr) |
| TW (1) | TW201350467A (fr) |
| UY (1) | UY34791A (fr) |
| WO (1) | WO2013169746A2 (fr) |
| ZA (1) | ZA201408825B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2916915A4 (fr) | 2012-11-07 | 2016-06-22 | Teva Pharma | Sels d'amine de laquinimod |
| US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2015168103A1 (fr) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod pour le traitement de patients atteints de sclérose en plaques récurrente rémittente (sep-rr) chez ayant un degré d'incapacité élevé |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2159804A (en) * | 1937-11-23 | 1939-05-23 | Du Pont | N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US6043006A (en) * | 1997-09-04 | 2000-03-28 | Fuji Photo Film Co., Ltd. | 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| ES2246238T3 (es) | 1999-06-07 | 2006-02-16 | Altana Pharma Ag | Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido. |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| NZ567088A (en) | 2005-10-19 | 2012-06-29 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20150065951A (ko) | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| AU2008242703B2 (en) | 2007-04-19 | 2011-08-18 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| EP2234485B1 (fr) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Préparations de laquinimod stables |
| KR20110048571A (ko) | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| WO2010070449A2 (fr) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Laquinimode très pur ou sel pharmaceutiquement acceptable de celui-ci |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| EP2228367A1 (fr) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH |
| JP2012530701A (ja) | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| PL2458992T3 (pl) | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
| WO2011019375A1 (fr) | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Traitement de troubles liés au fndc au moyen de laquinimod |
| CA2791711A1 (fr) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Traitement de l'arthrite de lupus a l'aide du laquinimod |
| DK2542079T3 (da) | 2010-03-03 | 2014-08-25 | Teva Pharma | Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat |
| SG183512A1 (en) | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
| EP2590653A4 (fr) | 2010-07-09 | 2014-01-01 | Teva Pharma | 5-chloro-4-hydroxy-1-méthyl-2-oxo-n-phényl-1,2-dihydroquinoléine-3-carboxamide, et des sels et des utilisations de celui-ci |
| WO2012006538A1 (fr) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | N-éthyl-n-phényl-1,2-dihydro-4-hydroxy-5-chloro-1-méthyl-2-oxoquinoléine-3-carboxamide deutéré, sels de ce composé et utilisations correspondantes |
| JP2012047974A (ja) * | 2010-08-26 | 2012-03-08 | Toshiba Corp | 映像表示装置及び映像表示方法 |
| WO2012050500A1 (fr) * | 2010-10-14 | 2012-04-19 | Lars Pettersson | 1,2-dihydro-4-hydroxy-2-oxo-quinoléine-3-carboxanilides en tant qu'activateurs d'ahr |
| AU2011338647A1 (en) | 2010-12-07 | 2013-07-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| IN2014MN00333A (fr) | 2011-07-28 | 2015-09-25 | Teva Pharma | |
| AU2012286701A1 (en) | 2011-07-28 | 2014-03-06 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| CA2851525A1 (fr) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Traitement de la sclerose en plaques par combinaison de laquinimod et de fingolimod |
-
2013
- 2013-05-02 TW TW102115767A patent/TW201350467A/zh unknown
- 2013-05-07 CA CA2873258A patent/CA2873258A1/fr not_active Abandoned
- 2013-05-07 EP EP13750833.9A patent/EP2697201A4/fr not_active Withdrawn
- 2013-05-07 WO PCT/US2013/039911 patent/WO2013169746A2/fr not_active Ceased
- 2013-05-07 KR KR20147034461A patent/KR20150022816A/ko not_active Withdrawn
- 2013-05-07 SG SG11201407447XA patent/SG11201407447XA/en unknown
- 2013-05-07 UY UY0001034791A patent/UY34791A/es not_active Application Discontinuation
- 2013-05-07 AU AU2013259779A patent/AU2013259779B2/en not_active Expired - Fee Related
- 2013-05-07 AR ARP130101569A patent/AR090975A1/es unknown
- 2013-05-07 EA EA201492029A patent/EA201492029A1/ru unknown
- 2013-05-07 HK HK15107804.4A patent/HK1207080A1/xx unknown
- 2013-05-07 US US13/888,709 patent/US8809537B2/en not_active Expired - Fee Related
- 2013-05-07 CN CN201380029448.XA patent/CN104395291B/zh not_active Expired - Fee Related
- 2013-05-07 IN IN2485MUN2014 patent/IN2014MN02485A/en unknown
- 2013-05-07 BR BR112014028121A patent/BR112014028121A2/pt not_active IP Right Cessation
- 2013-05-07 MX MX2014013664A patent/MX2014013664A/es unknown
- 2013-05-07 NZ NZ630549A patent/NZ630549A/en not_active IP Right Cessation
-
2014
- 2014-10-26 IL IL235338A patent/IL235338A0/en unknown
- 2014-12-02 ZA ZA2014/08825A patent/ZA201408825B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201407447XA (en) | 2015-02-27 |
| AU2013259779B2 (en) | 2017-06-08 |
| WO2013169746A2 (fr) | 2013-11-14 |
| EP2697201A4 (fr) | 2014-11-26 |
| TW201350467A (zh) | 2013-12-16 |
| BR112014028121A2 (pt) | 2017-06-27 |
| UY34791A (es) | 2013-11-29 |
| CN104395291A (zh) | 2015-03-04 |
| US8809537B2 (en) | 2014-08-19 |
| AR090975A1 (es) | 2014-12-17 |
| ZA201408825B (en) | 2016-07-27 |
| NZ630549A (en) | 2016-01-29 |
| EA201492029A1 (ru) | 2015-06-30 |
| CA2873258A1 (fr) | 2013-11-14 |
| HK1207080A1 (en) | 2016-01-22 |
| IL235338A0 (en) | 2014-12-31 |
| CN104395291B (zh) | 2017-07-28 |
| WO2013169746A3 (fr) | 2013-12-05 |
| EP2697201A2 (fr) | 2014-02-19 |
| US20130345256A1 (en) | 2013-12-26 |
| KR20150022816A (ko) | 2015-03-04 |
| MX2014013664A (es) | 2015-04-17 |
| AU2013259779A1 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10670A (fr) | ||
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| IN2014MN02485A (fr) | ||
| PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| PH12016501310B1 (en) | Pharmaceutical compositions comprising azd9291 | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| PL402710A1 (pl) | Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| AU2018297348A1 (en) | Compositions for parenteral administration of therapeutic agents | |
| PH12016502246A1 (en) | Carboxamide derivatives | |
| MX2016013431A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| EP3103453A4 (fr) | Composition médicinale comprenant un composé de carboxamide hétérocyclique diamino en tant qu'agent actif | |
| EP3493808A4 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
| HK1198296A1 (en) | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof | |
| IN2014MU00859A (fr) | ||
| WO2019004980A3 (fr) | Compositions pharmaceutiques orales solides d'étéxilate de dabigatran | |
| IN2013MU03421A (fr) | ||
| MX2016005539A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| MX2016013428A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| IN2013MU03309A (fr) | ||
| MX2018010652A (es) | Composiciones farmaceuticas. | |
| IN2014MU01194A (fr) | ||
| HK40052632A (en) | Methods and compositions for delivery of agents across the blood-brain barrier | |
| GB2569616B (en) | Sustained release oral pharmaceutical compositions of dicycloverine |